Table 2 Comparison of the clinical data and thyroid hormone levels in T2DM patients with or without progressive liver fibrosis

Sex (male/female)

34/59

229/264

0.079

Age (years)

71(66–78)

57(52–65)

0.000

Diabetes course (years)

10(6–19.5)

7(3–12)

0.000

Duration of treatment (years)

10(5–18.5)

6(1.75–12)

0.000

BMI (kg/m²)

26.79 ± 3.87

24.96 ± 3.36

0.000

Systolic pressure(mmHg)

135(124–149)

132(122–144.5)

0.214

Diastolic pressure(mmHg)

78(70.5–84)

82(76–90)

0.000

Waistline(cm)

96.04 ± 12.13

91.12 ± 9.79

0.000

Hipline (cm)

102(96–106.5)

99(94–103)

0.001

Waist hip ratio (WHR)

0.94(0.90–0.98)

0.92(0.89–0.96)

0.026

ALT(U/L)

15(11–20)

19(14–28)

0.000

AST(U/L)

17(15–20)

17(14–21)

0.575

AST/ALT

1.13(0.98–1.35)

0.86(0.70–1.07)

0.000

γ- GGT (U/L)

18(14–27.5)

24(17–34)

0.001

AKP(U/L)

90.0(73.0–110.5)

92.0(75.0–113.0)

0.477

FBG (mmol/L)

6.99(5.59–8.85)

7.70(6.22–10.23)

0.007

TG (mmol/L)

1.38(0.97–1.89)

1.50(1.02–2.24)

0.087

TC (mmol/L)

4.31 ± 1.08

4.64 ± 0.96

0.003

HDL (mmol/L)

1.15(0.94–1.37)

1.12(0.94–1.37)

0.971

LDL (mmol/L)

2.41(2.03–3.14)

2.80(2.24–3.36)

0.003

APO-A1(g/L)

1.26 ± 0.26

1.28 ± 0.25

0.451

APO-B(g/L)

0.85 ± 0.26

0.92 ± 0.22

0.003

FT3(pmol/L)

3.88 ± 0.53

4.03 ± 0.48

0.007

FT4(pmol/L)

12.79 ± 1.50

13.26 ± 1.50

0.006

TT3(nmol/L)

1.33(1.16–1.43)

1.39(1.25–1.55)

0.001

TT4(nmol/L)

83.36 ± 12.57

86.93 ± 16.34

0.018

FT3/FT4

0.306 ± 0.050

.307 ± 0.044

0.958

TSH (uIU/L)

2.2219(1.6204–3.2512)

2.0229(1.3759–2.8217)

0.028

HOMA-IR (CP)

3.1409(2.4986–3.8983)

3.2306(2.5629–3.9423)

0.441

FCP (ng/mL)

1.82(1.28–2.59)

1.79(1.17–2.58)

0.650

HbA1C (%)

7.60(6.80–8.85)

8.00(6.80–9.90)

0.173

FLI

40.30(19.81–61.26)

45.65(26.82–66.58)

0.090